Disclaimer

Access to the information and documents on this part of the website is restricted for regulato-ry reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.

DISCLAIMER – IMPORTANT

Due to applicable legal restrictions, the information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or any other jurisdiction in which such release, publication or distribution would be unlawful. We apologize for any inconvenience this may cause. Click here to return to the homepage.

Important information

The materials contained herein are not for general release, publication or distribution, directly or indirectly, in whole or in part, in or into Australia, Hong Kong, Canada, Ja-pan, New Zealand, Singapore, South Africa, the United States of America or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction. Access to the information and documents on this portion of the web-site is restricted for regulatory reasons. You are requested to review the following infor-mation and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.

 

The information contained in this section of the website of Oncopeptides AB (publ) (the “Company”) is (a) only intended for, and may only be accessed by, or distributed or dissem-inated, directly or indirectly, in whole or in part, to persons resident and physically present outside the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “United States”), Australia, Hong Kong, Ja-pan, Canada, New Zealand, Singapore or South Africa, and resident and physically present in a jurisdiction where to do so will not constitute a violation of the local securities laws or regu-lations of such jurisdiction, and (b) does not constitute an offer to sell or the solicitation of an offer to buy or acquire any securities of the Company in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such juris-diction.

 

The securities of the Company referred to in this section of the website (the “Securities”) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state of the United States for offer or sale as part of their distribution and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securi-ties laws of any state or other jurisdiction of the United States. The Securities have not been and will not be registered under the applicable securities laws of Australia, Hong Kong, Ja-pan, Canada, New Zealand, Singapore, South Africa or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold to or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or any other jurisdiction in which it would be unlawful or would require regis-tration or other measures.

 

Access to the information contained on this portion of the website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such infor-mation and documents. All persons who wish to have access to the documents contained in this section of the Company’s website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.

 

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

 

I therefore certify that:

 

  1. I am resident and physically present in a country outside the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore and South Africa;
  2. I am authorized to access the information and documents contained on this portion of the website without being subject to any legal restriction and without any further ac-tion required by the Company;
  3. I will not transmit or otherwise send any information contained in this website to pub-lications with a general circulation in the United States; and
  4. I have read, understand and agree to comply with all of the restrictions set forth above.

Press release

Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm

February 22, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has, together with HealthCap and Industrifonden (together the “Main Shareholders”), decided to, in order to further the Company’s continued development of its product candidate Ygalo, carry out a broadening of its shareholder base through a new share issue of SEK 650 million (the “Offering”). The Board of Directors of Oncopeptides has applied for a listing of the Company’s shares on Nasdaq Stockholm. Gladiator, SEB-Stiftelsen and Carnegie Asset Management (together the “Cornerstone Investors”) have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of SEK 196 million. Furthermore, the Main Shareholders have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of SEK 40 million. In connection with the Offering, the Company will also issue new shares as a result of the conversion of the Company’s bridge loans.

Nasdaq Stockholm has approved the application subject to customary conditions. First day of trading in the Company’s shares is expected to be February 22, 2017. Today the Company publishes a prospectus, the price and other terms of the Offering.

For further information please visit the company webpage:
www.oncopeptides.se